Swiss National Bank Ideaya Biosciences, Inc. Transaction History

Swiss National Bank

$150 Billion
Q3 2024

A detailed history of Swiss National Bank transactions in Ideaya Biosciences, Inc. stock. As of the latest transaction made, Swiss National Bank holds 133,100 shares of IDYA stock, worth $3.57 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares

133,100

Previous 124,700 6.74%

Holding current value

$3.57 Million

Previous $4.38 Million 3.7%

% of portfolio

0.0%

Previous 0.0%

11 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2024 Nov 07, 2024	BUY	$30.37 - $43.05 $255,108 - $361,620	8,400 Added 6.74%	133,100 $4.22 Million
Q2 2024 Aug 08, 2024	BUY	$34.37 - $43.46 $457,120 - $578,018	13,300 Added 11.94%	124,700 $4.38 Million
Q1 2024 May 07, 2024	BUY	$34.2 - $47.13 $899,460 - $1.24 Million	26,300 Added 30.9%	111,400 $4.89 Million
Q4 2023 Feb 06, 2024	SELL	$24.59 - $35.83 $538,521 - $784,677	-21,900 Reduced 20.47%	85,100 $3.03 Million
Q3 2023 Nov 08, 2023	BUY	$21.07 - $29.77 $77,959 - $110,149	3,700 Added 3.58%	107,000 $2.89 Million
Q2 2023 Aug 09, 2023	BUY	$13.33 - $25.53 $270,599 - $518,259	20,300 Added 24.46%	103,300 $2.43 Million
Q1 2023 May 10, 2023	SELL	$13.49 - $18.72 $132,202 - $183,456	-9,800 Reduced 10.56%	83,000 $1.14 Million
Q4 2022 Feb 08, 2023	BUY	$14.47 - $18.17 $30,387 - $38,157	2,100 Added 2.32%	92,800 $1.69 Million
Q3 2022 Nov 09, 2022	BUY	$9.24 - $15.79 $248,556 - $424,751	26,900 Added 42.16%	90,700 $1.35 Million
Q1 2022 May 09, 2022	BUY	$11.18 - $24.02 $51,428 - $110,492	4,600 Added 7.77%	63,800 $714,000
Q4 2021 Feb 08, 2022	BUY	$20.95 - $26.88 $1.24 Million - $1.59 Million	59,200 New	59,200 $1.4 Million

Others Institutions Holding IDYA

# of Institutions

216

Shares Held

80.8M

Call Options Held

69K

Put Options Held

20K

View Full List

About IDEAYA Biosciences, Inc.

Ticker IDYA
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 48,067,700
Market Cap $1.29B
Description
IDEAYA Biosciences, Inc., a synthetic lethality-focused precision medicine oncology company, focuses on the discovery and development of targeted therapeutics for patient populations selected using molecular diagnostics. The company's lead product candidates include IDE397, a methionine adenosyltransferase 2a inhibitor that is in Phase I clinica...

More about IDYA

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Swiss National Bank, based on Form 13F filings with the SEC.

News

Stay updated on Swiss National Bank with notifications on news.

Account

Swiss National Bank Ideaya Biosciences, Inc. Transaction History